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Purpose: We performed this study to evaluate the clinical presentation as well as the proper surgical intervention for ovarian metastasis 
from gastric cancers and these tumors were identified during postoperative follow-up. This will help establish the optimal strategy for im-
proving the survival of patients with this entity. 
Materials and Methods: 22 patients (3.2%) with ovarian metastasis were noted when performing a retrospective chart review of (693) 
females patients who had undergone a resection for gastric cancer between 1981 and 2008. The covariates used for the survival analy-
sis were the patient age at the time of ovarian relapse, the size of the tumor, the initial TNM stage of the gastric cancer, the interval to 
metastasis and the presence of gross residual disease after treatment for Krukenberg tumor. The cumulative survival curves for the pa-
tient groups were calculated with the Kaplan-Meier method and they were compared by means of the Log-Rank test. 
Results: The average age of the patients was 48.6 years (range: 24 to 78 years) and the average survival time of the 22 patients was 
18.8 months (the estimated 3-year survival rate was 15.8%) with a range of 2 to 59 months after the diagnosis of Krukenberg tumor. 
The survival rate for patients without gross residual disease was longer than that of the patients with gross residual disease (P=0.0003). 
In contrast, patient age, the size of ovarian tumor, the initial stage of gastric adenocarcinoma, the interval to metastasis and adjuvant 
chemotherapy were not prognostic indicators for survival after the development of ovarian metastasis. 
Conclusions: Early diagnosis and complete resection are the only possible hope to improve survival. As the 3-year survival rate after re-
section of Krukenberg tumor is 15.8%, it seems worthwhile to consider performing tumorectomy as the second cytoreduction.
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Introduction
The prognosis of ovarian metastases or Krukenberg tumor is 
known to be poor. Different from the West, it is not rare disease in 
Korea as it is tumor that has metastasized from gastric cancer and 
gastric cancer is prevalent in Korea. Krukenberg tumor occur in 
0.3~6.7% of the operated gastric cancer patients, and its incidence 
is much higher in the autopsies of gastric cancer patients (33~41%).
(1,2) Numerous studies on Krukenberg tumor have been reported 
in Korea and other countries, nonetheless, most of them are on 
synchronous Krukenberg tumors, and there are relatively few stud-
ies on the incidence and treatment outcomes of metachronous 
Krukenberg tumor that developed during the postsurgical follow-
up observation period. It has been reported that the incidence 
of Krukenberg tumor detected during the follow-up observa-
tion period after radical gastric resection or the second surgery is 
3~4.4％, the median survival  time is 12.4~17 months,(3,4) and 
the inci  dence and prognosis are slightly different depending on the 
reports. Therefore, we analyzed the incidence of Krukenberg tumor 
that developed during the follow-up observation period after the 
resection of the primary gastric cancer, and the clinicopathological 
features of the Krukenberg tumors were confirmed by the second 
surgery. The treatment methods, the survival rate and the factors 
mediating effects on them were examined.
Copyright © 2011 by The Korean Gastric Cancer Association www.jgc-online.orgJun SY and Park JK
32
Materials and Methods
Among the 41 patients who were pathologically diagnosed with 
Krukenberg tumor after the second surgery at the Department of 
Surgery, Samsung Changwon Hospital, Sungkyunkwan Univer-
sity School of Medicine during 27 years from 1981 to 2008, this 
study was conducted on 22 patients who were considered to have 
Krukenberg tumor that metastasized from gastric cancer, based 
on the history of surgery for gastric cancer. First, the incidence of 
Krukenberg tumor that originated from gastric cancer after gas-
trectomy was examined by assessing the number of female patients 
who underwent surgery for gastric cancer during the same period. 
In addition, the age of onset of the 22 Krukenberg tumor patients, 
the menopause status, the tumor markers, the tumor node metas-
tasis (TNM) disease stage according to the American Joint Com-
mittee on Cancer (AJCC) 6th edition(5) and the presence of factors 
that could mediate effects on the survival rate were examined by 
retrospectively assessing the histopathological grade of cell dif-
ferentiation, the interval from the first surgery to the development 
of tumor, the surgical methods for Krukenberg tumor, whether or 
not more than 4 cycles of adjuvant chemotherapy was performed 
and the survival rate after the second surgery, based on the medical 
records. The follow-up observation of the patients was performed 
using the database at the outpatient department or by telephone 
follow-ups, and the mean follow-up period was 25.２ months. The 
survival rate of the Krukenberg tumor patients was analyzed by the 
Kaplan-Meier method and the Log-Rank test, and P-values＜0.05 
were determined to be significant. All the statistical analyses were 
performed using the SPSS for Windows 12.0.
Results
The Krukenberg tumor patients were confirmed by the second 
surgery after the primary surgery for gastric cancer, and 22 patients 
were thought to have ovarian tumor that metastasized from gastric 
cancer. In regard to the primary cancer of the 41 Krukenberg tu-
mor patients diagnosed after the second surgery during the same 
period, 53.7% of them had gastric cancer. In addition, there were 
693 female patients who received gastrectomy after the diagnosis 
of gastric cancer during the same period and so the incidence of 
Krukenberg tumor that developed during the follow-up period af-
ter gastrectomy was 3.2%. 
As for the major symptoms of Krukenberg tumor, lower ab-
dominal discomfort and intermittent abdominal pain were noted 
in 10 cases (45.5%), no symptoms other than the detection of an 
ovarian mass by abdominal ultrasonography during regular physi-
cal check-ups was noted in ６cases (27.3%), palpation of a mass 
in the lower abdomen was noted in 4 cases (18.2%) and abdominal 
distention associated with ascites, abscess within the pelvis and 
fever was noted in one case each (4.5%). As for the diagnostic 
method, except for 1 patient with an intrapelvic abscess, 21 cases 
(95.5%) were diagnosed with an ovarian mass that was suspicious 
to be malignant by the abdominal sonography and abdominal CT 
performed prior to the second surgery. These patients and their 
masses were subsequently definitely diagnosed by examining the 
frozen sections during surgery.
The interval from the first surgery to the resurgery for Kruken-
berg tumor was on average 16.5 months (range: 3~34 months). 
The mean age of the patients was 48.6 years (range: 24~78 years), 
13 patients were premenopausal women (59.1%) and there were 9 
postmenopausal women (40.9%). During the first surgery, concern-
ing the disease stage of the primary tumor according to the AJCC 
TNM disease stage classification, 6th edition, there was 1 case of 
stage 0 (4.5%), there were 2 cases of stage IA (9.1%), there were 4 
cases of stage IB (18.2%), there were 6 cases of stage II (27.3%), 
there were 4 cases of stage IIIA (18.2%) and 1 case of stage IV 
(4.5%). The disease stage II was the most prevalent. In addition, 
with regard to the depth of lesions, there was 1 case of Tis (4.5%), 
there were 7 cases of T1 (31.8%), there were 6 case of T2a/2b 
(27.3%), there were 7 cases of T3 (73.8%) and 1 case of T4 (4.5%). 
Regarding lymphovascular involvement, there were 5 cases of N0 
(22.7%), 9 cases of N1 (40.9%) and 1 case of (4.5%). Regarding the 
histologic grade, 10 patients had moderately differentiated tumor 
(45.5%) and 8 patients had well differentiated tumor (36.4%).
As for the clinical characteristics of Krukenberg tumor, the av-
erage long axis was 12.9 cm (range: 4.6~18.０cm), 18 patients had 
bilateral tumors (81.8%) and 4 patients had unilateral tumor (18.2%). 
As the recurrence patterns, 11 patients had tumor limited to the 
ovary (50.0%), 5 patients recurred within the pelvic cavity (22.7%) 
and 6 patients’ tumor had metastasized to organs other than the 
abdomen and the pelvis (27.3%). Concerning surgical treatments, 
laparotomy was performed on all 22 patients, and bilateral oo-
phorectomy was performed on all 22 patients. Hysterectomy was 
performed simultaneously on 10 patients, including 5 patients for 
whom invasion to the uterus was suspected. There were 14 patients 
without macroscopic residual tumors after tumor resection (63.6%). 
Including the 3 patients (13.6%) whose tumor had metastasized to 
the great omentum at the time of the second surgery, 8 (36.4%) Krukenberg Tumor from Gastric Cancer Treated
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patients’ tumor metastasized to the intraperitoneal peritoneum and 
thus the complete resection of the metastasized ovarian lesions 
was difficult and only palliative resection was performed, and this 
resulted in the presence of macroscopic residual cancer cells. After 
the second surgery, more than 4 cycles chemotherapy was per-
formed for 15 patents (68.2%). Eight patients (36.4%) were treated 
with the combination of Taxane and platinum and 7 patients (31.8%) 
were treated with 5-FU monotherapy.
The average postsurgical survival time of all the patients was 1
８.8 months (range: 2.0~59.０ months, including the 2 surviving 
patients), the 3-year survival rate was 15.8%, the survival period of 
the 16 patients (R0) for whom tumor resection could be performed 
without leaving residual tumors was on average 23.7 months, and it 
was significantly higher than the 6.0 months average survival time 
of the 8 patients (R2) for whom only palliative resection was per-
formed because of the invasion to the adjacent pelvis, etc. (P=0.0003)
(Fig. 1). However, the age of the patient at the time of the diagnosis 
of tumors, the menopausal status, the AJCC TMN disease stage of 
the primary tumor, the grade of differentiation of the tumor cells, 
the interval from the first surgery to tumor development, the tumor 
size and the status of chemotherapy were not associated with the 
survival rate (Table 1).
Among all 22 patients, 9 patients were tested for two tumor mark-
ers, serum CEA and CA-125, which may be of help to make an early 
diagnosis of Krukenberg tumor. Of the 9 patients, the CA-125 level 
was shown to be higher than normal (normal: lower than 35 U/ml) in 
8 patients out of the 9 patients (88.9%), and the average value was 45.5
±25.3 U/ml. The CEA was elevated in 1 patient (11.1%) to 16.2 ng/
ml, which was slightly high, and the rest of the patients were within 
the normal range (normal: lower than 10 ng/ml). 
Discussion
The metastasis mechanism of Krukenberg tumor is particular, 
for example, it has been reported to develop even after the radical 
resection of early gastric cancer,(6) and so we studied the clini-
cal characteristics, including the metastasis patterns. It has been 
reported that Krukenberg tumor is rare and its prognosis is poor, 
Fig. 1. Overall survival curves for the patients with Krukenberg tumor 
from gastric cancer. The patients without gross residual disease sur-
vived longer than the patients with gross residual disease (P=0.0003).
Table 1. Factors associated with survival aft  er the development of 
Krukenberg Tumor from gastric cancers treated by resection
Variables No. (%) P-value*
Age at the time of ovarian relapse NS
  <50 years (premenopause) 13 (59.1)
  ≥50 years (postmenopause)   9 (40.9)
AJCC TMN stage of primary gastric lesion NS
  EGC   1 (4.5)
  IIa    2 (9.1)
  Ib   4 (18.2)
  II   6 (27.3)
  IIIa   4 (18.2)
  IIIb   2 (9.1)
  IV   1 (4.5)
Histology of primary lesion NS
  Well diff  erentiated   8 (36.4)
  Mod. diff  erentiated 10 (45.4) 
  Poorly diff  erentiated   4 (18.2)
Interval to ovarian relapse  NS
  <1 year   8 (36.4)
  1~2 years   7 (31.8)
  >2 years   7 (31.8)
Size of ovarian tumor NS
  <5 cm   1 (4.5)
  5~10 cm    9 (40.9)
  >10 cm 12 (54.5)
Chemotherapy regimen  NS
  Taxane+Platinum   8 (36.4)
  5 FU   7 (31.8)
  None   7 (31.8)
Gross residual disease aft  er treatment 0.0003
  Absence  14 (63.6)
  Presence   8 (36.4)
Total 22  (100)
NS = not signifi  cant; AJCC = American Joint Commitee on Cancer; 
TMN = tumor node metastasis; EGC = early gastric cancer; FU = 
fl  uorouracil. *P>0.05.Jun SY and Park JK
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yet the studies performed in the West on Krukenberg tumor were 
on patients with primary colon cancer in most cases. Thus, it was 
considered that the incidence and prognosis in Korea, where gas-
tric cancer is more prevalent, would be different．In our study, 
statistical analysis was not performed on all the 693 gastric cancer 
patients treated during the same period and so comparison with 
all the patients who had undergone a curative gastric resection for 
stomach cancer was difficult. It was particular that 6 patients (27.3%) 
belonged to the AJCC disease stage 2, which was the most preva-
lent stage. Although this may be due to several reasons, we can 
speculated that this due to the effect of mass screening programs 
that have been widely performed recently, and so the number of 
patients lower than stage 2 became abundant. Indeed, according 
to the result of studies recently performed by Nam et al.(7) at the 
National Cancer Center, of the 18,414 patients who received physi-
cal check-ups, gastric cancer was detected in 81 patients (0.44%). 
Among these 81 patients, 80% had early gastric cancer, which 
shows that the disease stage of the diagnosed gastric cancer has 
become substantially lower.
Krukenberg tumor was reported for the first time in 1896 by 
Freidrich Ernst Krukenberg. Afterward, the definition of the dis-
ease and the diagnostic criteria were very confusing. Initially, all 
metastatic ovarian cancers were termed as Krukenberg tumor. 
Since the confusion was induced by the term, Novak and Gray(8) 
in 1938 proposed the diagnostic criteria that classical Krukenberg 
tumor should composed of signet-ring cell carcinoma within a 
dense fibroblastic stroma in the ovary. The WHO(9) in 1973 estab-
lished the diagnostic standard, which is the diagnostic standard that 
has been applied until now. Almost all Krukenberg tumors are the 
diffused type according to the Luaren’s classification of primary 
gastric cancer. Nevertheless, it has been reported that although it is 
a very rare tumor, this tumor is almost always associated with dis-
seminated disease like the intestinal type adenocarcinoma of gastric 
cancer, which has metastasizes to the ovary.(10) Involvement of 
ovary by intestinal type gastric carcinoma compared with that on 
signet-ring cell carcinoma that result in the Krukenberg tumor may 
be confused with primary ovarian mucinous neoplasm, but such 
cases were not detected at our series. 
Several mechanism have been suggested to explain the progres-
sion and recurrence pathway of gastric cancer such as lymphatic 
spread, hematogenous spread, direct invasion, peritoneal seeding, 
etc. Among them, the incidence of hematogenous recurrence is 
highest. Although Krukenberg tumor also may be induced by com-
plex mechanisms, as a factor for metastasis, lymph node metastasis 
is considered to be the most potent risk factor for recurrence.(11,12) 
Therefore, if the national cancer screening program, including 
esophago-gastroscopic screening, becomes active and so the diag-
nosis of early gastric cancer is increased and appropriate treatments 
could be administered early, the incidence of Krukenberg tumor 
also may be changed, and the distribution of the primary disease 
stage may become different. 
It has been reported that the incidence of Krukenberg tumor is 
approximately 30~40% of all metastatic ovarian cancers, it is a rare 
tumor (approximately 2% of all ovarian cancers), and the progno-
sis is awful to the level that all the patients die within 1 year after 
diagnosis.(13) In the east Asia where the incidence of gastric can-
cer is high, Krukenberg tumor has been shown to occur relatively 
frequently as approximately 4.4~6.7% within 3 years after surgery 
in the female patients who have received gastrectomy.(1,3,11) In 
this study, similarly, although it was difficult to infer the incidence 
of metachronous tumor during the same period, during the rela-
tively long follow-up observation (27 years), approximately 3.2％ 
of the patients who received gastrectomy after the diagnosis of 
gastric cancer developed Krukenberg tumor. The primary lesion of 
Krukenberg tumor is in the order of the colon, pancreas and breast 
in the West, and the prognosis varies depending on the primary le-
sion. On the other hand, in the east Asia, the cause is gastric cancer 
in many cases, followed by cancer of the colon, breast, small intes-
tine, gallbladder and bladder.(13-15) 
Most patients with Krukenberg tumors present with symtoms 
related to ovarian tumors including abdominal pain and the tumor 
can be palpated in more than 50% of cases. Rarely, patients may 
present with abnormal uterine bleeding.(16）In such situation, 
early clinical symptoms of Krukenberg tumors are vague and the 
primary gastric cancer may not manifest itself until later in most 
cases. So making an early diagnosis is difficult and this results in 
often detecting inoperable cases. In our study, unexpectedly, there 
was only one patients case in whom typical ascites was detected by 
a physical examination, and other than that, most early symptoms 
were lower abdominal pain, discomfort, etc. and they were con-
sidered to be nonspecific symptoms, so making the early diagnosis 
was difficult, and this may lower the postsurgical survival rate. 
Therefore, the most important factor for allowing the complete re-
section of tumors may be physicians being aware of the possibility 
of Krukenberg tumor. In several studies, it has been reported that 
premenopausal Krukenberg tumor patients were more prevalent 
and the tumor was multicentric in most cases.(17) In our study, 
similarly, there were 13 premenopausal patients (59.1%) and 18 Krukenberg Tumor from Gastric Cancer Treated
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patients (81.8%) with bilateral tumor. Thus, additional tests must be 
performed on the bilateral ovarian tumors detected in premeno-
pausal women after they have undergone surgery for gastric cancer. 
Koyama et al.(18）have reported that even if ascites, abdominal 
pain or other symptoms are not detected by physical examina-
tion, for patients with the past history of surgery for gastric cancer 
or other digestive tract cancer, the presence or absence of ascites 
should be assessed by abdominal ultrasonography or CT, and ef-
forts should be made to diagnose ovarian cancer early. In addition, 
Krukenberg tumor should be always be suspected if on CT the 
tumor is bilateral and it is characterized by lobulated solid tumors, 
and enhancement with contrast medium is noticeable in the ovary. 
So, only an early diagnosis that allows the complete resection of 
tumor can improve the survival rate of Krukenberg tumor, and 
McGill et al.(19）stated that gynecologists should comprehensively 
examine the upper abdominal area during surgery, and surgeons 
should comprehensively examine the lower abdominal area during 
surgery. This should be encouraged now that endoscopic submu-
cosal dissection, laparoscopic gastrectomy and robotic surgery are 
becoming more common.
Concerning the prognosis of Krukenberg tumor, the radical re-
section of Krukenberg tumor without leaving macroscopic residual 
lesions is difficult in many cases, and it has been reported that the 
median duration of survival ranges from 7.7 to 14.0 months.(1,3,13) 
In our study, the average survival rate was 18.8 months and this in-
cludes 2 patients who are still alive 22 and 59 months after surgery, 
the overall 3-year survival rate was approximately 15.7% and the 
prognosis was not good, but it was better than that of other reports. 
The reasons that the survival rate in our study were slightly high 
may be diverse, yet it may be due to the proportion of patients in-
cidentally detected during physical examination. So an early diag-
nosis was possible for ６ patients, and the patients for whom com-
plete resection of Krukenberg tumor was difficult were transferred 
to other hospitals and so there were relatively fewer patients with 
the incomplete resection of tumors. Yada-Hashimoto et al.(2) have 
reported that even for patients with metastatic ovarian cancer origi-
nated from tumors in non-intrapelvic organs, including Krukenberg 
tumor, a postsurgical 5-year survival rate higher than 19% could be 
anticipated. They also mentioned that if the metastatic ovarian can-
cer is completely resected, then better results than anticipated could 
be obtained, so they emphasized aggressive resection. Of course, 
for all metachronous Krukenberg tumors, the feasibility of resec-
tion may be determined according to the extraovarian metastasis at 
the time of ovarian metasectomy. The survival rate for our patients 
who underwent aggressive tumor resection without residual cancer 
was on average 23.7 months, and this was significantly higher than 
the 6.0 months for the average survival period of the patients who 
underwent palliative resection because of tumor invasion to other 
organs and the adjacent pelvis. This suggests that only an early 
diagnosis and efforts to remove tumor-burdened intrapelvic organs 
could increase the survival period. In regard to the factors exerting 
effects on the postsurgical survival rate, most studies have reported 
that the age of patients at the time of the diagnosis of Krukenberg 
tumor, the menopause status, the primary tumor site, the grade of 
differentiation of the tumor cells and the disease stage were not 
associated with the postsurgical survival rate, and similar to other 
malignant tumors, only aggressive resection could increase the 
survival rate.(1,3,15) It has recently been reported that postsurgical 
adjuvant chemoradiation therapy had a major impact on the local 
recurrence in patients with resectable gastric cancer.(20) However, 
the effect of adjuvant chemoradiation therapy after the resection 
of Krukenberg tumor is still controversial. Numerous studies have 
reported that it did not mediate effects on the survival rate.(1,21) In 
our study, similarly, the survival rate of the 15 patients who under-
went more than 4 cycles of the therapy was not different from the 
15 patients who did not receive adjuvant therapies, and the survival 
rate was also not associated with the types of chemotherapeutic 
agents.
When performing colectomy for colorectal cancer, for women 
older than 40 years, attempts to perform prophylactic bilateral 
ovariectomy have been made in some cases,(22) but this is still 
controversial for the patients who have undergone  gastrectomy．
Yamamoto et al.(23) stated that prophylactic ovariectomy could be 
considered if it is not possible to resect the tumor from the ovary 
without macroscopic abnormalities and if the CEA value is high 
after washing the peritoneal cavity with approximately 100 ml sa-
line. The feasibility of the early detection of Krukenberg tumor by 
tumor markers has been reported in several studies, yet most of the 
markers have been shown to be non-specific. It has been reported 
that the rapid elevation of the CA-125 level has been widely ap-
plied as a marker of ovarian cancer and this is of help to make the 
early diagnosis of Krukenberg tumor.(2) In our study, there were 
only 2 patients (9.1%) with the rapid increase of the CA-125 level 
to higher than 100 U/ml and the percentage of patients with a 
higher than average value were only 45.5%, and so this marker was 
not of great help. As compared with the observation that the CEA 
and CA 19-9 levels were not changed in most patients, among 9 
patients for whom the measurement of CA-125 was performed, it Jun SY and Park JK
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was shown to be elevated in 8 patients. Since CA-125 was helpful 
to predict the development of Krukenberg tumor after surgery for 
cancer in the digestive tract, it may be better to test the CA-125 
tumor marker during the follow-up observation period. 
In summary, the incidence of the metastatic ovarian cancer that 
developed during the follow-up observation period after gastrecto-
my (Krukenberg tumor) was 3.2%. Even if surgery was performed, 
the mean survival period was 18.8 months, and the prognosis 
was poor. Nonetheless, the 3-year survival rate was 15.8%, and 
so attempts to resect tumors as the second tumor reduction seem 
worthwhile. Although several factors may mediate effects on the 
survival rate, the most important factor that affects the survival rate 
is the complete resection of tumors. Yet the recurrence patterns are 
important, and aggressive efforts not to leave residual cancer cells 
at the second surgery are required. In addition, for all female gastric 
cancer patients who have undergone a gastrectomy and especially 
young premenopausal women, a suspicion of Krukenberg tumor 
can help make an early diagnosis by comprehensively assessing the 
CA-125 level and other tumor markers, as well as by performing 
lower abdominal ultrasonography. 
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